Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03621553
Other study ID # STU 062010-055
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date July 1, 2010
Est. completion date December 30, 2026

Study information

Verified date November 2023
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the relationship between vitamin-D status and severity of sarcoidosis, and the effects of vitamin-D repletion in vitamin-D insufficient patients with sarcoidosis. Half the patients with sarcoidosis who are vitamin-D insufficient will receive standard vitamin-D supplementation via standard regimen while the other half will receive a placebo. Sarcoidosis patients who are vitamin-D sufficient will also act as controls.


Description:

Sarcoidosis is a multi-system inflammatory disease characterized by T-helper lymphocyte hyperactivity leading to granulomatous inflammation. The granuloma cells autonomously convert 25-hydroxy-vitamin-D (25OHD) to the active metabolite 1,25-dihydroxy-vitamin-D (1,25OH2D) independent of normal feedback control but dependent on substrate (25OHD) concentration. Circulating 1,25OH2D exerts both anti-inflammatory and mineral metabolic actions. Deficiency of 25OHD limits substrate-dependent 1,25OH2D synthesis, diminishes anti-antigenic innate immunity and augments pro-inflammatory adaptive immunity. Thus, low vitamin-D stores could aggravate sarcoid inflammation while repletion of vitamin-D stores could mitigate inflammation in sarcoidosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date December 30, 2026
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Stable medical condition defined as no hospitalization or emergency room visit in the previous 3 months - No evidence of active pulmonary or systemic infection - No other active inflammatory disease, - No active malignancy. - Normal serum ionized calcium level Exclusion Criteria: - Hospitalization or emergency room visit in the previous 3 months - Evidence of active pulmonary or systemic infection - Evidence of active other inflammatory disease - Evidence of active malignancy - Elevated serum ionized calcium level

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ergocalciferol
Vitamin D2 50,000 units
Placebo
Sugar pill manufactured to mimic ergocalciferol 50,000 units
Calcium Citrate with Vitamin D2
To meet the recommended minimum daily dietary requirements

Locations

Country Name City State
United States University of Texas Southwestern Medical Center, and Parkland Health and Hospital System Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (4)

Bolland MJ, Wilsher ML, Grey A, Horne AM, Fenwick S, Gamble GD, Reid IR. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open. 2013 Oct 23;3(10):e003562. doi: 10.1136/bmjopen-2013-003562. — View Citation

Capolongo G, Xu LH, Accardo M, Sanduzzi A, Stanziola AA, Colao A, Agostini C, Zacchia M, Capasso G, Adams-Huet B, Moe OW, Maalouf NM, Sakhaee K, Hsia CC. Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Investig Med. 2 — View Citation

Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, van Daele PL. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res. 2014 Nov;29(11):2498-503. doi: 10.1002/jbmr.2262. — View Citation

Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):575-9. doi: 10.1016/j.jsbmb.2004.03.038. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in lung function from baseline (Measurement at end of study)/(measurement at enrollment) Baseline and 24 weeks
Secondary Change in King's Sarcoidosis Questionnaire Score Standard validated questionnaire for assessing the impact of sarcoidosis on quality of life. Questions address symptoms, activities and psychosocial impacts of disease. It consists of 29 questions on general health, medications, and symptoms in lung, skin, and eyes, summed to derive a total score. Each question is scored on a scale of 1 (worst) to 7 (best). Minimum total score = 5 (poorest health). Maximum total score = 203 (best health). Baseline, 12 and 24 weeks
Secondary Change in six minute walk distance (Measurement at end of study)/(measurement at enrollment) Baseline and 24 weeks
Secondary Change in blood cell counts from complete blood count (CBC) (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in metabolic profile from complete metabolic panel (CMP) (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in serum vitamin-D metabolite concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in serum angiotensin converting enzyme (ACE) concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in serum serum gamma-globulin concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in serum C-reactive protein (CRP) concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in serum tumor Necrosis factor-alpha (TNF-alpha) concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in serum interferon-gamma (IFN-gamma) concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Changes in serum interleukin concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in 24 hour urine calcium/creatinine ratio (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in 24 hour urine deoxypyridinoline concentration (Measurement at study point)/(initial measurement at enrollment) Baseline, 12 and 24 weeks
Secondary Change in fractional lung tissue volume on computed/positron emission tomography (PET/CT) (Measurement at end of study)/(measurement at enrollment) Baseline and 24 weeks
Secondary Change in Fluoro-deoxyglucose (FDG) uptake on PET/CT (Measurement at end of study)/(measurement at enrollment Baseline and 24 weeks
Secondary Change in bone density z-score (Measurement at end of study)/(measurement at enrollment) Baseline and 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04008069 - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00326534 - Rickettsial Genesis to Sarcoidosis in Denmark N/A
Completed NCT00274352 - A Study of Adalimumab to Treat Sarcoidosis of the Skin Phase 2
Completed NCT00373555 - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis N/A
Recruiting NCT00470327 - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed NCT00512967 - The Occurence of Inflammation and Oxidative Stress in Lung Diseases N/A
Recruiting NCT01745237 - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed NCT00369980 - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Completed NCT06396910 - TB and Sarcoidosis Granuloma
Completed NCT04156789 - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting NCT02916459 - EBUS-TBNA vs Flex 19G EBUS-TBNA N/A
Recruiting NCT02827734 - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed NCT02546388 - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01139710 - Sarcoidosis-associated Pulmonary Hypertension N/A
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4